By Using Mind.Px, Patients Achieve PASI75 Faster than Treatment-as-Usual Cohort
SAN DIEGO, CA – October 20, 2022 – Interim clinical utility and patient outcomes data regarding Mindera Health’s Mind.Px™ test from the ongoing MATCH study were recently presented at the Fall Clinical Dermatology Conference 2022 in Las Vegas, one of the largest US-based dermatology educational meetings. These data validate the willingness of physicians to incorporate Mind.Px test results into their biologic decision making for psoriasis patients as well as demonstrate improved patient outcomes when the test reports were followed.
In the United States, psoriasis affects more than three percenti of the population, leading to healthcare costs of more than $110 billion annually.ii Furthermore, successful patient responses to currently available biologic treatments are roughly 52 percentiii,…